The CFL1 (Cofilin-1) antibody is a critical tool for studying the dynamics of actin cytoskeleton regulation. Cofilin-1. encoded by the CFL1 gene, is a small (18-21 kDa) actin-binding protein that plays a central role in severing and depolymerizing filamentous actin (F-actin), facilitating cytoskeletal remodeling essential for processes like cell motility, cytokinesis, and intracellular trafficking. Its activity is tightly regulated by phosphorylation (inactivation) and dephosphorylation (activation), primarily through LIM kinase and SSH phosphatase pathways. Dysregulation of CFL1 is implicated in cancer metastasis, neurodegenerative diseases, and immune cell dysfunction.
CFL1 antibodies are widely used in research to detect cofilin-1 expression, localization, and post-translational modifications via techniques such as Western blotting, immunofluorescence, and immunohistochemistry. They help elucidate mechanisms of cytoskeletal dynamics in pathological conditions, including tumor invasiveness and synaptic plasticity defects. Specific antibodies targeting phosphorylated CFL1 (e.g., at Ser3) are employed to study inactivation states, offering insights into signaling pathways like Rho GTPase or ROCK. Commercial CFL1 antibodies are typically raised in rabbits or mice, validated for cross-reactivity in human, mouse, and rat samples. Their applications span cancer biology, neuroscience, and immunology, making them indispensable for exploring cell motility, apoptosis, and disease biomarkers.